Polivy (polatuzumab vedotin-piiq) vs Ezharmia (valemetostat tosilate)
Polivy (polatuzumab vedotin-piiq) vs Ezharmia (valemetostat tosilate)
Polivy (polatuzumab vedotin-piiq) is an antibody-drug conjugate specifically approved for the treatment of certain types of B-cell non-Hodgkin lymphoma, particularly for patients who have relapsed or are refractory to at least two prior therapies. It works by targeting the CD79b protein on B cells and delivering a cytotoxic agent directly to these cells. In contrast, Ezharmia (valemetostat tosilate) is an experimental, orally administered EZH1/2 dual inhibitor with potential use in treating hematological malignancies and solid tumors, but as of the knowledge cutoff date, it has not received regulatory approval. Patients should consult with their healthcare provider to determine the most appropriate treatment based on their specific medical condition, treatment history, and the current approval status of the medication.
Difference between Polivy and Ezharmia
| Metric | Polivy (polatuzumab vedotin-piiq) | Ezharmia (valemetostat tosilate) |
|---|---|---|
| Generic name | Polatuzumab vedotin-piiq | Valemetostat tosilate |
| Indications | Relapsed or refractory diffuse large B-cell lymphoma | T-cell lymphoma (under investigation, not yet approved) |
| Mechanism of action | Antibody-drug conjugate targeting CD79b | Inhibitor of EZH1 and EZH2 methyltransferase activity |
| Brand names | Polivy | Ezharmia (investigational, not yet a brand name) |
| Administrative route | Intravenous infusion | Oral (assumed, based on available information) |
| Side effects | Neutropenia, anemia, thrombocytopenia, peripheral neuropathy, fever, diarrhea | Not fully characterized, under investigation |
| Contraindications | Hypersensitivity to polatuzumab vedotin-piiq or any of its excipients | Not yet established |
| Drug class | Antibody-drug conjugate | Epigenetic modifier |
| Manufacturer | Genentech, Inc. | Daiichi Sankyo |
Efficacy
Efficacy of Polivy (polatuzumab vedotin-piiq) in Lymphoma
Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody-drug conjugate used in the treatment of certain types of lymphoma, specifically diffuse large B-cell lymphoma (DLBCL). The efficacy of Polivy was evaluated in a pivotal clinical trial that focused on patients with relapsed or refractory DLBCL who had previously received multiple therapy lines. The study demonstrated that Polivy, when combined with bendamustine and a rituximab product (a combination known as "BR"), resulted in a significant improvement in overall response rate (ORR) and complete response rate (CRR) compared to BR alone. This improvement in response rates translated into a survival benefit for patients who received the Polivy combination therapy.
The trial's results were compelling enough to lead to the accelerated approval of Polivy by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory DLBCL, not otherwise specified, after at least two prior therapies. The approval was based on the high rate of durable responses achieved with the Polivy combination therapy, which addressed a significant unmet medical need in this patient population.
Efficacy of Ezharmia (valemetostat tosilate) in Lymphoma
Ezharmia (valemetostat tosilate) is an investigational, orally administered, selective inhibitor of EZH1 and EZH2 methyltransferase activity. These enzymes are part of the epigenetic regulatory system and are implicated in the pathogenesis of various types of cancer, including lymphoma. Valemetostat tosilate has shown promise in early clinical trials for the treatment of lymphoma, particularly in T-cell lymphoma (TCL) and B-cell lymphoma subtypes.
In clinical studies, valemetostat tosilate demonstrated a favorable safety profile and encouraging anti-tumor activity in patients with relapsed or refractory lymphomas. The efficacy outcomes have included partial and complete responses in a subset of patients with T-cell lymphoma, suggesting that valemetostat tosilate may offer a new therapeutic option for this challenging-to-treat patient population. However, as an investigational drug, valemetostat tosilate is still undergoing clinical trials to further evaluate its efficacy and safety for the potential treatment of lymphoma.
Regulatory Agency Approvals
Polivy
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
Ezharmia
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Polivy or Ezharmia today
If Polivy or Ezharmia are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us